FierceBiotech· @FierceBiotech · X·· 28 天前AI 评分40
AI 导读
恒瑞如何成为中国生物医药创新的首选来源?在与BMS和GSK达成数十亿美元交易后,该公司的研发负责人向Fierce讲述了推动其成功的因素以及未来的方向。https://www.fiercebiotech.com/biotech/hengrui-has-become-go-source-china-biopharma-innovation-whats-its-secret
正文
How did Hengrui become a go-to source of Chinese biopharma innovation? After multibillion-dollar deals with BMS and GSK, the company's R&D leader tells Fierce what's driving its success and where it goes next. https://www.fiercebiotech.com/biotech/hengrui-has-become-go-source-china-biopharma-innovation-whats-its-secret
来源:FierceBiotech · x.com